Vergent Bioscience Announces Publication in The Annals of Surgical Oncology Demonstrating Abenacianine with Intraoperative Molecular Imaging Improved Tumor Visualization During Lung Cancer Surgery

Vergent Bioscience Names Adam Gridley as Chief Executive Officer

Vergent Bioscience Initiates Phase 3 VISUALIZE 2 Pivotal Study of Abenacianine (VGT-309) for Tumor Visualization During Lung Cancer Surgery

Vergent Bioscience Presents Phase 2B VISUALIZE Results Demonstrating Abenacianine for Injection (VGT-309) with Intraoperative Molecular Imaging Improved Tumor Visualization During Lung Surgery

Vergent Bioscience to Present Data on Abenacianine for Injection (VGT-309) at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery

Vergent Bioscience Completes Enrollment in Phase 2 VISUALIZE Trial Evaluating Potential of Abenacianine for Injection (VGT-309) to Improve Tumor Visualization During Cancer Surgery

Vergent Bioscience Data Published in The Annals of Thoracic Surgery Demonstrate VGT-309 May Help Surgeons Visualize Tumor Tissue in the Lung During Surgery

Vergent Bioscience Presents Phase 2 Data Showing VGT-309 Visualizes Tumors in the Lung During Surgery

Vergent Bioscience to Present New Efficacy Results from Phase 2 Clinical Trial of VGT-309 at Annual Meeting of The Society of Thoracic Surgeons